Skip to main content

Farxiga News (Page 2)

FDA Medwatch Alert: SGLT2 inhibitors: Drug Safety Communication - FDA Warns Medicines May Result in a Serious Condition of Too Much Acid in the Blood

ISSUE: FDA is warning that the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, a serious condition where the body produces high levels of blood...

FDA Approves Xigduo XR (dapagliflozin and metformin hydrochloride) for Type 2 Diabetes

WILMINGTON, Del., October 30, 2014 – AstraZeneca today announced that the U.S. Food and Drug Administration has approved once-daily Xigduo XR (dapagliflozin and metformin hydrochloride...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Heart Failure, Congestive Heart Failure, Chronic Kidney Disease, Diabetes, Type 2

Farxiga patient information at Drugs.com